hTNF抗肿瘤药物医疗产品欧洲委员会授予MolMed公司的用于治疗肝细胞癌(HCC)的抗肿瘤药物NGR—hTNF罕见病药物身份.此项决定基于欧洲医药评价署(EMEA)罕见病医疗产品委员会的肯定意见.NGR—hTNF还因相同适应证被FDA授予罕见病药物身份.代号为NGR008,有40位患者参与的研究该化合物单独给约治疗肝癌的Ⅱ期临床试验的主要...
NGR-hTNF is a vascular targeting agent that consists of a modified form of human TNF-α fused with an NGR peptide. The NGR peptide moiety of the compound acts by selectively targeting blood vessels, where TNF is released, resulting in the destruction of the tumor's blood supply and subseque...
Methods: Patients (pts) with advanced MPM were treated with low-dose NGR-hTNF given at 0.8 碌g/m2 as 1-hour intravenous infusion every 3 weeks (q3w). This dose was previously selected in phase I trial based on dynamic imaging changes and preliminary clinical activity. The trial had a 2...
白海航鸽子王(永年店),邯郸市永年区东召庄村绿菌盛宴小吃店。白海航鸽子王(永年店)的抖音主页、视频、合集以及作品的粉丝量、点赞量。来抖音,记录美好生活!
The tolerability and disease control of NGR-hTNF 0.8 microg/m(2) weekly warrant additional evaluation in patients with advanced MPM.doi:10.1016/S1359-6349(09)71724-0Gregorc, V.Ceresoli, G.L.Zucali, P.A.De Braud, F.G.Bajetta, E....
NGR-hTNF is a VTA exploiting a tumor-homing peptide (NGR) that selectively binds to aminopeptidase N (CD13) overexpressed on tumor blood vessels. In preclinical models, NGR-hTNF has shown potent anti-vascular and antitumor activity, both at low and at high doses. Patients with recurrent or...
RESULTS: NGR-hTNF was well tolerated. No treatment-related grade 3 to 4 toxicities were detected, most common grade 1 to 2 adverse events being short-lived, infusion-time related chills (50.0%). One partial response and 12 stable diseases were observed, yielding a disease control rate of ...
Milan (Italy), 12 November 2012 – The Board of Directors of MolMed S.p.A. (MLM.MI), chaired by Prof. Claudio Bordignon, today reviewed and approved the interim financial report at 30 September 2012. The most important elements wereNGRhTNF Molmed...
Anticancer agent -- NGR-hTNF.The article reports on the findings of the clinical trials of anticancer agents which were presented at the American Society of Clinical Oncology (ASCO) meeting in Chicago, Illinois.EBSCO_bspManufacturing Chemist
靶向抗肿瘤NGR-hTNF实体瘤化学治疗的疗效绝大部分依赖于化疗药物透过肿瘤组织远端肿瘤细胞的能力.实验证明:由天冬酰胺-甘氨酸-精氨酸(NGR)基序组成的环肽和线性肽可选择性识别肿瘤血管,具有被开发为作用于肿瘤或血管生成组织的抗肿瘤药物的配doi:CNKI:SUN:YXJZ.0.2011-11-011邢爱敏VIP药学进展...